

**SI Figure S4.** Modeling of PF-2771 exposure, pharmacodynamic marker modulation, and efficacy in the HCC1806 tumor model (TNBC/basal-like breast cancer; symbols are individual animals; lines are PK/PD modeling results). (*left panel*). Single-dose PK/PD study determines the exposure-response relationship of PF-2771 on intra-tumoral phospho-HH3-Ser<sub>10</sub>. (*center panel*) Chronic dosing TGI study analysis. Multiple lines shown on each plot represent model simulations for animals with differing tumor sizes at the start of the study (time = 0). (*right panel*) PK/PD model-predicted tumor cell growth and kill rates are depicted as functions of time in the TGI study (green solid lines are growth rates, red dotted lines are the kill rates).

